Johnson & Johnson (NYSE:JNJ) already has RYBREVANT approved across multiple EGFR-mutated advanced lung cancer settings. New long-term data are now strengthening the clinical evidence behind the drug.
READ ALSO: Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
In the final overall-survival analysis of the Phase 3 PAPILLON study, first-line RYBREVANT plus chemotherapy delivered a median overall survival of 34.3 months in patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations, compared with 27.9 months for chemotherapy alone. J&J described the result as the longest reported median overall survival in this patient population.
Bull Case
The survival duration is particularly notable given the historically poor outcomes associated with EGFR exon 20 insertion-positive lung cancer. According to J&J, historical median overall survival in this population has ranged from approximately 16 to 24 months, while historical five-year survival has been reported at just 8%. In PAPILLON, patients receiving RYBREVANT plus carboplatin-pemetrexed chemotherapy reached a median overall survival of nearly three years.
The comparison was complicated by crossover. After their disease progressed, eligible patients initially assigned to chemotherapy could cross over to second-line RYBREVANT, and ultimately, 76% of eligible patients in the chemotherapy arm did so. A prespecified analysis accounting for that crossover showed a 43% reduction in the risk of death with first-line RYBREVANT plus chemotherapy, with a hazard ratio of 0.57.
Longer-term disease control provided another positive data point. Progression-free survival through second disease progression, or PFS2, reached 28.3 months with the RYBREVANT combination versus 17.5 months with chemotherapy, which reflects an improvement of more than 10 months. The findings also build on PAPILLON’s earlier primary analysis, which demonstrated a statistically significant improvement in progression-free survival, the trial’s primary endpoint. Those results supported global approvals of the regimen in this setting.
DON’T MISS: Can GSK’s Hepatitis B Breakthrough Become a £2 Billion Opportunity?
For J&J, RYBREVANT already extends beyond this particular mutation, as the drug is approved in multiple EGFR-mutated advanced NSCLC settings, including common EGFR mutations and exon 20 insertion mutations.
Bear Case
The headline survival numbers still require careful interpretation. In the protocol-specified final overall-survival analysis, the 34.3-month median OS with RYBREVANT plus chemotherapy versus 27.9 months with chemotherapy produced a hazard ratio of 0.87, a 95% confidence interval of 0.66 to 1.14, and a P-value of 0.307. The protocol-specified final OS analysis therefore did not reach statistical significance.
J&J points to the high crossover rate as an important factor when interpreting the result. The prespecified analysis accounting for crossover showed a statistically significant overall-survival benefit, but investors should distinguish that analysis from the protocol-specified final OS result.
Safety also remains relevant in this context. Although J&J reported no new safety signals with longer follow-up, the most common treatment-related adverse events occurring in at least 30% of patients included paronychia and neutropenia, each at 60%, and rash at 58%.
Conclusion
PAPILLON gives J&J another long-term data point for an already approved RYBREVANT regimen, but the details matter as much as the headline. Patients receiving RYBREVANT plus chemotherapy reached a median overall survival of 34.3 months versus 27.9 months with chemotherapy alone. The protocol-specified final OS analysis did not reach statistical significance, however, against the backdrop of substantial crossover to RYBREVANT in the chemotherapy arm.
The prespecified crossover-adjusted analysis and longer PFS2 results provide additional support for the regimen, while the earlier progression-free-survival results have already helped establish its regulatory position. For J&J, the significance is therefore less about creating a new treatment opportunity overnight and more about adding longer-term evidence behind a regimen that is already part of its EGFR-mutated lung cancer portfolio.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
